Soonmee Cha

List of Publications by Year
in descending order

72 papers	4,304 citations	249298 26 h-index	129628 63 g-index
73 all docs	73 docs citations	73 times ranked	7092 citing authors

#	Article	IF	Citations
1	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathologica, 2022, 143, 109-113.	3.9	11
2	Susceptibility-Weighted Imaging of Intravascular Lymphoma of the Central Nervous System. JAMA Neurology, 2022, 79, 86.	4.5	6
3	ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. American Journal of Neuroradiology, 2022, 43, 455-461.	1.2	3
4	Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas. Frontiers in Neuroscience, 2022, 16, 787755.	1.4	18
5	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	0.6	10
6	Functional outcomes after resection of middle frontal gyrus diffuse gliomas. Journal of Neurosurgery, 2022, 137, 1-8.	0.9	8
7	Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	22
8	Machine Learning Tools for Image-Based Glioma Grading and the Quality of Their Reporting: Challenges and Opportunities. Cancers, 2022, 14, 2623.	1.7	6
9	Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era. Korean Journal of Radiology, 2021, 22, 1858-1874.	1.5	4
10	Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2021, 154, 83-92.	1.4	8
11	Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Scientific Reports, 2021, 11, 14377.	1.6	2
12	Feasibility of Simulated Postcontrast MRI of Glioblastomas and Lower-Grade Gliomas by Using Three-dimensional Fully Convolutional Neural Networks. Radiology: Artificial Intelligence, 2021, 3, e200276.	3.0	15
13	MRI Features May Predict Molecular Features of Glioblastoma in *Isocitrate Dehydrogenase* Wild-Type Lower-Grade Gliomas. American Journal of Neuroradiology, 2021, 42, 448-456.	1.2	34
14	Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease. International Journal of Hematology-Oncology and Stem Cell Research, 2021, 15, 260-264.	0.3	0
15	Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting. Neuro-Oncology Practice, 2021, 8, 91-97.	1.0	1
16	Highâ€grade neuroepithelial tumor with *BCOR* exon 15 internal tandem duplicationâ€"a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathology, 2020, 30, 46-62.	2.1	69
17	Disruption of Frontal Aslant Tract Is Not Associated with Long-Term Postoperative Language Deficits. World Neurosurgery, 2020, 133, 192-195.	0.7	23
18	A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. Scientific Reports, 2020, 10, 11852.	1.6	41

#	Article	IF	Citations
19	Involvement of the Olfactory Apparatus by Gliomas. American Journal of Neuroradiology, 2020, 41, 712-717.	1.2	2
20	Machine Learning Decision Tree Models for Differentiation of Posterior Fossa Tumors Using Diffusion Histogram Analysis and Structural MRI Findings. Frontiers in Oncology, 2020, 10, 71.	1.3	26
21	Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro-Oncology, 2020, 22, 1516-1526.	0.6	5
22	Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. American Journal of Neuroradiology, 2019, 40, 1804-1810.	1.2	27
23	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica, 2019, 138, 877-881.	3.9	21
24	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	5.1	315
25	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. American Journal of Roentgenology, 2018, 210, 621-628.	1.0	75
26	Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma. Journal of Neuro-Oncology, 2018, 138, 549-556.	1.4	16
27	Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging. Neuro-Oncology Practice, 2018, 5, 234-240.	1.0	10
28	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research, 2018, 24, 5850-5859.	3.2	118
29	Differentiation of Cerebellar Hemisphere Tumors: Combining Apparent Diffusion Coefficient Histogram Analysis and Structural MRI Features. Journal of Neuroimaging, 2018, 28, 656-665.	1.0	20
30	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. American Journal of Neuroradiology, 2018, 39, 1201-1207.	1.2	323
31	Tailoring Radiology Resident Education Using Aggregated Missed-Cases Data. Journal of the American College of Radiology, 2018, 15, 1013-1015.	0.9	2
32	Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight, 2018, 3, .	2.3	26
33	Association of early changes in ^{1}H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro-Oncology, 2017, 19, now159.	0.6	24
34	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology, 2017, 19, now254.	0.6	155
35	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. American Journal of Neuroradiology, 2017, 38, 795-800.	1.2	132
36	Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. Journal of Neuro-Oncology, 2017, 132, 171-179.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Current Clinical Brain Tumor Imaging. Neurosurgery, 2017, 81, 397-415.	0.6	281
38	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, 1247-1262.	1.9	175
39	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, spcone.	1.9	2
40	Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. Journal of the Neurological Sciences, 2017, 381, 83-87.	0.3	11
41	Biologically aggressive regions within glioblastoma identified by spin-lock contrast T1 relaxation in the rotating frame (T1ρ) MRI. Radiology Case Reports, 2017, 12, 827-832.	0.2	6
42	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Translational Oncology, 2017, 10, 895-903.	1.7	15
43	Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain Tumor Research and Treatment, 2017, 5, 1.	0.4	67
44	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.0	22
45	Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. Journal of Neuro-Oncology, 2017, 134, 213-219.	1.4	21
46	Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines, 2016, 4, 24.	1.4	12
47	NIMG-43. APPLICATION OF AN ADVANCED DIFFUSION-WEIGHTED MRI TECHNIQUE TO CHARACTERIZE GLIOMA MICROSTRUCTURE AND RELATIONSHIP TO HISTOPATHOLOGY. Neuro-Oncology, 2016, 18, vi134-vi134.	0.6	0
48	Advanced MR Imaging Techniques in Daily Practice. Neuroimaging Clinics of North America, 2016, 26, 647-666.	0.5	14
49	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Academic Radiology, 2016, 23, 1073-1082.	1.3	14
50	Metastasis in Adult Brain Tumors. Neuroimaging Clinics of North America, 2016, 26, 601-620.	0.5	41
51	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Journal of Neuro-Oncology, 2016, 130, 171-179.	1.4	24
52	The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro-Oncology, 2016, 18, 87-95.	0.6	33
53	Adult-onset central nervous system hemophagocytic lymphohistiocytosis: a case report. BMC Neurology, 2015, 15, 203.	0.8	13
54	Modern Brain Tumor Imaging. Brain Tumor Research and Treatment, 2015, 3, 8.	0.4	157

#	Article	IF	Citations
55	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology, 2015, 2015, 1-4.	0.5	16
56	CNS angiitis as a brain tumor mimic with a branching vascular abnormality on T2* MRI. Neurology, 2015, 85, 1819-1820.	1.5	2
57	Surgical Management of Intracranial Neuroenteric Cysts: The UCSF Experience. Journal of Neurological Surgery, Part B: Skull Base, 2015, 76, 475-479.	0.4	9
58	Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. American Journal of Roentgenology, 2015, 205, 1075-1085.	1.0	38
59	From Shades of Gray to Microbiologic Imaging: A Historical Review of Brain Abscess Imaging:*RSNA Centennial Article*. Radiographics, 2015, 35, 1555-1562.	1.4	12
60	Intrameningioma Metastasis of Breast Carcinoma. Rare Tumors, 2014, 6, 49-52.	0.3	14
61	Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology, 2012, 14, 942-954.	0.6	183
62	Magnetic Resonance of 2-Hydroxyglutarate in *IDH1*-Mutated Low-Grade Gliomas. Science Translational Medicine, 2012, 4, 116ra5.	5.8	161
63	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology, 2012, 108, 491-498.	1.4	149
64	Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR Imaging. Radiology, 2010, 254, 564-576.	3.6	148
65	Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2009, 253, 486-496.	3.6	365
66	Neuroimaging in Neuro-Oncology. Neurotherapeutics, 2009, 6, 465-477.	2.1	130
67	CNS Tumors. Topics in Magnetic Resonance Imaging, 2006, 17, 63-68.	0.7	9
68	Update on brain tumor imaging. Current Neurology and Neuroscience Reports, 2005, 5, 169-177.	2.0	24
69	Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. Journal of Neurosurgery, 2005, 103, 428-438.	0.9	155
70	Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. American Journal of Neuroradiology, 2005, 26, 266-73.	1.2	178
71	Perfusion MR Imaging of Brain Tumors. Topics in Magnetic Resonance Imaging, 2004, 15, 279-289.	0.7	99
72	Perfusion MR imaging: basic principles and clinical applications. Magnetic Resonance Imaging Clinics of North America, 2003, 11, 403-413.	0.6	81